ROS1 and non-small cell lung carcinoma: Guibert et al. had successfully identified CD74-ROS1 rearrangements in two patients [183], whereas Mezquita et al. tried to assess the clinical utility of ROS1 fusion and resistance mutations using an amplicon-based liquid biopsy test in NSCLC patients.